28TH NOVEMBER: CURRENT CHALLENGES IN CLINICAL TRIALS

Lung Cancer Europe will hold an event on 28th November at the EU Parliament to highlight the current challenges in clinical trials across Europe

Within the occasion of this event, the 3rd edition of the LuCE report, which highlights some of the challenges still faced regarding research, will be presented.

For the third consecutive year, LuCE will hold an event at the EU Parliament in which relevant stakeholders will discuss the current situation of clinical research landscape in lung cancer across Europe.  Mr. Alojz Peterle, President of MEPs Against Cancer Group will hold the meeting.

LuCE will also present the main outcomes of the 3rd edition of the LuCE report “Challenges in Lung Cancer Clinical Trials”. This 3rd Report focusses on clinical trials and welcomes the progress made in lung cancer treatment in recent years. However, it also seeks to highlight some of the challenges still faced regarding research. These challenges include lack of funds, time delays, recruitment barriers, absent research areas and a lack of knowledge and awareness by both patients and healthcare professionals. These aspects are some of the priorities that must be addressed in order to improve the quality of and access to lung cancer clinical trials.

This event will offer a great opportunity to bring together policy makers, regulators, physicians, patient advocates, and media to define the current gaps in lung cancer research in which collaboration between all involved actors is highly required to improve the outcomes for the whole community.

The agenda of the event is shown below:

16:30 – 16:45 – Introductory remarks

  • Alojz Peterle, Member of the European Parliament, Group of the European People’s Party

16:45- 17:00 – Brief Lung Cancer Europe (LuCE) presentation and feedback on the previous report

  • Stefania Vallone, President of Lung Cancer Europe (LuCE)

17:00– 17:15 – Current clinical trial situation in the EU

  • Denis Lacombe, General Manager of the European Organization for Research and Treatment of Cancer (EORTC)

17:15 – 17:30 – Taking part in a clinical trial

  • Christian Smith-Plank, lung cancer survivor and member of the Board of Directors of Lung Cancer Europe (LuCE)

17:30 – 17:45 – Industry’s perspective on patient advocates involvement in clinical trials

  • Sini Eskola, Regulatory Drug Development and Manufacturing Director of the European Federation of Pharmaceutical Industries and Associations (EFPIA)

17:45 – 18:00 – Cross-border clinical trials in the EU

  • Tanja Cufer, MD, Ph.D., Medical Faculty at the University of Ljubljana, Slovenia

18:00 – 18:15 – LuCE report and call to action

  • Stefania Vallone, President of Lung Cancer Europe (LuCE)

18:15 – 18:30 – Q&A & Closing remarks

  • Stefania Vallone, President of Lung Cancer Europe (LuCE)

For additional information about the event, please contact Alfonso Aguarón at [email protected].